arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AIM ImmunoTech Inc.

AIM
$0.15 ▼ -0.01 (-5.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

AIM ImmunoTech Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.6M
Dividend Yield —
Revenue Growth 4.0% ↘
Op. Margin —
ROIC -24.4% ↗
FCF / Share $-0.27 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$26.00K
↑ +4.0% —
Net Income Profit after all expenses
$-3.02M
↑ +18.4% —
FCF / Share Free cash flow per share
$-0.27
↑ +57.1% —
Long-Term Debt Long-term obligations
$3.62M
↓ -14.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health ↑
63
Cash Quality ↑
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters